ST AIA-PACK HbA1C
ST AIA-PACK HbA1C is designed for in-vitro diagnostic use for the quantitative measurement for percent concentration of hemoglobin A1C (HbA1C) in EDTA whole blood on the TOSOH AIA systems.
Part #: 0025218
Manufacturers:
Description
Hemoglobin A1C (HbA1C) is a stable molecule that is formed in hemoglobin (Hb) with sugars in two steps by non-enzymatic reaction. Labile HbA1C is first formed where Schiff base is derived from the N-terminal amino group of hemoglobin β-chain with an aldehyde group of glucose. Labile HbA1C is then converted to stable HbA1C by the Amadori rearrangement. Percent concentration of stable HbA1C increases with the average concentration of glucose in the blood. Life time of stable HbA1C is approximately 100-120 days. Stable HbA1C reflects the long-term blood glucose level. HbA1C is, therefore, the most important marker for long-term assessment of the glycemic state for diabetic patients. According to the Diabetes Control and Complications Trial (DCCT), control of glucose level is important to prevent the complications from diabetes. Measurement of HbA1C demonstrates the improvement of glucose metabolism control and the policy of treatment for diabetic patients.
Technical specifications
| Kit name | ST AIA-PACK HbA1c |
| Method | Enzyme Immunoassay (EIA) |
| Assay principle | Two-site immunoenzymometric assay |
| Assay sample | EDTA whole blood |
| Calibrators | 0, 3.3, 6.3, 9.3, 12.5, 15.5 % |
| Standardization | IFCC reference method |
| Calibration stability | 90 days |
| Assay range | 3 - 14 % |
| Reaction time | 10 minutes |
| Hook effect | >25 % |
| Storage | 2 - 8oC |
Refer to the product Instruction-For-Use (IFU) for complete details.